Navigation Links
YM BioSciences presents CYT387 and CYT997 data at international cancer conference
Date:2/11/2010

MISSISSAUGA, ON, Feb. 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.

The CYT387 poster, "A novel, potent and selective dual inhibitor of JAK1 and JAK2 for treatment of myeloproliferative neoplasms and cancer" was presented Thursday, February 11th at 7:30 pm AEDT.

Dr. Chris Burns, Research Director at YM Australia, presented the poster on CYT387 which is currently being investigated in a Phase I/II clinical trial for myelofibrosis at Mayo Clinic, in Rochester, MN. The poster describes important preclinical data obtained for CYT387 including comparison to other reported JAK inhibitors. In a number of different assays CYT387 is shown to be a potent and selective JAK1/JAK2 inhibitor, with a promising activity profile for treatment of myeloproliferative neoplasms (MPNs) and other diseases.

The CYT997 poster, "Vascular targeting and anti-tumour efficacy of orally administered CYT997 in combination with cisplatin in a DLD-1 human colon adenocarcinoma xenograft model." is being presented Friday, February 12th at 8:00pm AEDT ('/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BioSciences granted two US patents for AeroLEF(R)
2. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
3. YM BioSciences reports second quarter 2010 operational and financial results
4. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
5. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
6. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
7. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
8. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
9. YM BioSciences announces result of Cytopia shareholder vote
10. Profectus Biosciences to Present at Key Investor Conference in January 2010
11. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") ... its Oral Amphotericin B (Oral Amp B) drug ... by ImmuneCarta®, the immune monitoring business unit of ... Oral Amp B in reactivating latent HIV viral ... treatment with antiretroviral therapy. Memory ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)...   Sterne, Kessler, Goldstein & Fox P.L.L.C. , ... DC , announced today that it has filed ... with the U.S. Patent and Trademark Office (USPTO) on ... Inc. (Nasdaq: BRLI).  These IPR petitions aim to nullify ... Inc. These patents have been asserted against GeneDx in ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it ... a lawsuit in U.S. District Court in Delaware ... Laboratories,Inc., for infringement of U.S. Patent Nos. 6,200,604 ... Cephalon product FENTORA(R) (fentanyl buccal,tablet) [C-II]. The 6,200,604 ...
... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided ... Executive Officer, and,Darlene Deptula-Hicks, Executive Vice President and ... corporate update at the Seventh Annual,Needham and Company ... 2008 at 2:00 p.m., (Eastern Daylight Time) at ...
... changes and further organizational ... consolidation ... Paul LaViolette to retire ... that President and Chief Executive,Officer Jim Tobin will be extending his tenure at the Company. The ...
Cached Biology Technology:Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 2Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals 3iCAD to Present at Seventh Annual Needham and Company Biotechnology and Medical Technology Conference 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... spiciness that is irresistible to some, but intolerable to ... their findings to develop a new drug candidate for ... inflammation or other problems. They reported their progress on ... in ACS, Journal of Medicinal Chemistry . , ... had pegged a compound called capsaicin as the active ...
(Date:8/20/2014)... Your chairs, synthetic rugs and plastic bags could one ... waste rather than petroleum, scientists are now reporting. The ... help the world deal with its agricultural and plastic ... . , Athanassia Athanassiou, Ilker S. Bayer and colleagues ... plastic,s popularity is constantly growing. In 2012, its production ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... Center for Climate Change (BC3) has analysed the expected economic impact ... the Kyoto Protocol for the period 2008-2012 and for the phase ... come out on top in comparison to sectors such as industrial ... Spain have an impact on the economy, in other words, making ...
... (VBI) at Virginia Tech have constructed a mathematical and ... to simulate the cellular and molecular changes underlying chronic ... to explore different interactions of cells in the immune ... in the colon, and identify intervention points to perhaps ...
... HOUSTON -- A novel approach detects genetically abnormal cells in ... abnormalities found in tumor cells and increase in number with ... scientists at The University of Texas MD Anderson Cancer Center ... Lung cancer patients in the study also had many times ...
Cached Biology News:CO2 reduction policies in Spain strengthen the services sector 2Math model of colon inflammation singles out dangerous immune cells 2Math model of colon inflammation singles out dangerous immune cells 3UT MD Anderson study ties abnormal cells in blood to lung cancer 2UT MD Anderson study ties abnormal cells in blood to lung cancer 3
Request Info...
Guinea Pig Complement...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
Biology Products: